Fortress Biotech, Inc. (FBIOP)

Fortress Biotech, Inc. (FBIOP) Healthcare & Pipeline Overview

Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes a diverse portfolio of pharmaceutical and biotechnology products, including dermatology and oncology treatments. With a focus on late-stage product candidates and strategic collaborations, Fortress Biotech aims to address unmet medical needs and drive long-term growth in the healthcare sector.

What Is the Investment Thesis for FBIOP?

Fortress Biotech presents a mixed investment profile. The company's diverse pipeline of dermatology and oncology products offers potential growth catalysts, particularly with late-stage candidates like Cosibelimab and CAEL-101. A gross margin of 65.8% indicates pricing power. However, the company's profitability, reflected in a P/E ratio of 21.18, needs to be considered against the backdrop of ongoing R&D expenses and potential regulatory hurdles. Upcoming clinical trial results for key pipeline assets and potential FDA approvals represent significant catalysts. Potential risks include clinical trial failures, regulatory setbacks, and market competition. Investors should closely monitor the progress of key clinical programs and the company's ability to secure partnerships and funding to support its development efforts.

Based on FMP financials and quantitative analysis

FBIOP Key Highlights

• Market Cap of $159.33M reflects its position as a smaller player in the biotechnology industry.
• P/E Ratio of 21.18 indicates how much investors are willing to pay for each dollar of earnings.
• Profit Margin of 6.4% demonstrates the company's ability to generate profit from its revenue.
• Gross Margin of 65.8% suggests strong pricing power and efficient cost management in product sales.
• Beta of 1.41 indicates higher volatility compared to the overall market.

Who Are FBIOP's Competitors?

FBIOP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are FBIOP's Key Strengths?

• Diverse pipeline of product candidates.
• Established dermatology product line.
• Strategic collaborations with research institutions.
• Experienced management team.

What Are FBIOP's Weaknesses?

• Dependence on successful clinical trial outcomes.
• Limited financial resources compared to larger pharmaceutical companies.
• Regulatory risks associated with drug development.
• Competition from established players in the biotechnology industry.

What Could Drive FBIOP Stock Higher?

• Clinical trial results for Cosibelimab in metastatic cancers.
• FDA approval decision for CAEL-101 in amyloid light chain amyloidosis.
• Expansion of the dermatology product line through new product launches.
• Advancement of early-stage product candidates through preclinical and clinical development.
• Strategic partnerships for product development and commercialization.

What Are the Key Risks for FBIOP?

• Financial-distress signal — its Altman Z-Score of -4.35 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for key product candidates.
• Regulatory setbacks and delays in drug approvals.
• Market competition from established pharmaceutical companies.
• Dependence on successful fundraising to support research and development.
• Patent expirations and generic competition.

What Are the Growth Opportunities for FBIOP?

• Growth opportunity 1: Advancing Cosibelimab for metastatic cancers represents a significant growth opportunity. The global market for cancer therapies is projected to reach $200 billion by 2026. Positive clinical trial results and subsequent FDA approval could drive substantial revenue growth for Fortress Biotech. The company's ability to secure strategic partnerships for commercialization will be crucial.
• Growth opportunity 2: The development of CAEL-101 for amyloid light chain amyloidosis offers another promising avenue for growth. This rare disease market has limited treatment options, presenting a significant unmet need. Successful clinical trials and regulatory approval could position CAEL-101 as a key therapy in this space, driving revenue growth and market share. The timeline for potential approval is estimated within the next 2-3 years.
• Growth opportunity 3: Expanding the dermatology product line, including Ximino and Targadox, provides a stable revenue stream and opportunities for market penetration. The global dermatology market is expected to reach $35 billion by 2028. Fortress Biotech can leverage its existing sales and marketing infrastructure to drive growth in this segment. Focus on product innovation and strategic partnerships can further enhance its market position.
• Growth opportunity 4: The development of CUTX-101 for Menkes disease, a rare genetic disorder, presents a unique growth opportunity. Orphan drug designation could provide regulatory and financial incentives. Successful development and commercialization of CUTX-101 could establish Fortress Biotech as a leader in the treatment of rare genetic diseases. The timeline for potential approval is estimated within the next 3-5 years.
• Growth opportunity 5: Leveraging the oligonucleotide platform and advancing preclinical product candidates such as ONCOlogues represents a long-term growth opportunity. This platform could lead to the development of novel therapies for various diseases. Strategic partnerships and collaborations will be essential for advancing these preclinical programs. The potential market for oligonucleotide-based therapies is significant, with continued advancements in drug delivery technologies.

What Opportunities Does FBIOP Have?

• Expansion into new therapeutic areas.
• Strategic partnerships for product development and commercialization.
• Acquisition of complementary technologies or products.
• Orphan drug designation for rare disease treatments.

What Threats Does FBIOP Face?

• Clinical trial failures.
• Regulatory setbacks.
• Market competition.
• Patent expirations.

What Are FBIOP's Competitive Advantages?

• Proprietary drug formulations and intellectual property.
• Established sales and marketing infrastructure for dermatology products.
• Strategic collaborations with universities and research institutes.
• Diverse pipeline of product candidates across various therapeutic areas.

What Does FBIOP Do?

Fortress Biotech, Inc., established in 2006 and based in Bay Harbor Islands, New York, is a biopharmaceutical company dedicated to developing and commercializing pharmaceutical and biotechnology products. Originally named Coronado Biosciences, Inc., the company rebranded to Fortress Biotech in April 2015. Fortress Biotech markets a range of dermatology products, including Ximino capsules for acne, Targadox for severe acne, Exelderm cream for fungal infections, Ceracade for dry skin, Luxamend for wound care, and Accutane capsules for severe acne. The company's pipeline includes late-stage product candidates such as intravenous Tramadol for post-operative pain, CUTX-101 for Menkes disease, MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for EGFR mutation-positive NSCLC, CAEL-101 for amyloid light chain amyloidosis, Triplex vaccine for cytomegalovirus, and CEVA101 for traumatic brain injury. Additionally, Fortress Biotech is developing early-stage and preclinical product candidates targeting various cancers and genetic disorders, leveraging collaborations with universities, research institutes, and pharmaceutical companies to advance its research and development efforts.

What Products and Services Does FBIOP Offer?

• Develops and commercializes pharmaceutical products.
• Focuses on dermatology and oncology treatments.
• Markets dermatology products like Ximino and Targadox.
• Develops late-stage product candidates like Cosibelimab and CAEL-101.
• Advances early-stage product candidates for various cancers.
• Collaborates with universities and research institutes.
• Develops preclinical product candidates through its oligonucleotide platform.

How Does FBIOP Make Money?

• Develops pharmaceutical products through internal research and development.
• Commercializes products directly or through partnerships.
• Generates revenue from sales of dermatology products.
• Out-licenses or sells developed products to other companies.

What Industry Does FBIOP Operate In?

Fortress Biotech operates within the competitive biotechnology industry, characterized by rapid innovation and high regulatory scrutiny. The company's focus on developing and commercializing pharmaceutical and biotechnology products places it alongside companies like COEP, CUE, EQ, GNTA, and IPSC. The industry is driven by increasing demand for novel therapies and advancements in drug development technologies. Fortress Biotech's success depends on its ability to navigate the complex regulatory landscape, secure funding for research and development, and effectively commercialize its products. The biotechnology industry is expected to continue growing, driven by an aging population and increasing prevalence of chronic diseases.

Who Are FBIOP's Key Customers?

• Patients with dermatological conditions like acne and fungal infections.
• Patients with cancer and other serious diseases.
• Hospitals and clinics that prescribe and administer their products.
• Pharmacies that dispense their medications.

Company Profile

Fortress Biotech, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Bay Harbor Islands, US. The company is led by CEO Lindsay Allan Rosenwald. FBIOP has traded publicly since 2017.

F-Score 2/9Financial Health

Fortress Biotech, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.35 places it in the distress zone, a signal of elevated financial risk.

ROE 164%Key Financial Metrics

Return on equity for Fortress Biotech, Inc. stands at 163.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 35.8%, showing how much profit it generates from its asset base. FBIOP trades at a trailing price-to-earnings ratio of 0.76, below the Healthcare sector average of ~23x. A current ratio of 2.86 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 132.4%, the inverse of the P/E and a quick read on earnings relative to price.

FBIOP Valuation & Market Position

With a $159.33M market cap, Fortress Biotech, Inc. sits in the micro-cap segment of the market. Relative to its peer group, FBIOP's quantitative score of 32/100 is roughly in line with the peer average of 40/100.

FY2026 estForward Outlook

Wall Street analysts project Fortress Biotech, Inc. revenue of about $79.9M for fiscal 2026, with EPS near $2.40.

Net buyingInsider Activity

Over the past six months, Fortress Biotech, Inc. insiders filed 3 SEC Form 4 transactions — 0 sales and 3 purchases. On net that is roughly 954K shares acquired (about $6K) — insiders putting money in tends to read as conviction.

FBIOP Financials

FBIOP Latest News

No recent news available for FBIOP.

FBIOP Analyst Consensus

FBIOP MoonshotScore

Common Questions About FBIOP (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources